Glaucoma is a leading cause of blindness, and African Americans and other minorities have a higher risk for the disease.
Penn Medicine researchers have identified three gene variants that may contribute to the development of glaucoma in those of African ancestry, according to research published recently in the journal Cell. Primary open-angle glaucoma is a leading cause of blindness, and African Americans have a higher risk for the disease.
“Our work is an important step toward defining subgroups of glaucoma, providing the capability for early screening, and discovering targetable pathways for personalized therapeutic interventions,” study author Rebecca Salowe said in a press release. “There is an urgent need for large genetic studies to identify novel targets for screening and therapeutic intervention in African ancestry individuals.” Salowe is a research project manager in the lab of senior author Joan O’Brien, M.D., a professor of Ophthalmology and director of the Penn Center for Genetics of Complex Disease.
Much of the research of the genes involved in glaucoma have not assessed the variants in minority populations. As of 2019, only 2% of all genome-wide association studies have been conducted in people whose ancestry is tied to Africa.
O’Brien and Salowe’s research involved more than 11,200 people of African ancestry. They found two particular variants that correlated with primary open-angle glaucoma. The variants discovered were rs1666698, tied to the gene DBF4P2, and rs34957764, linked to ROCK1P1. A third variant was also identified (rs11824032 tied to ARHGEF12), which was associated with cup-to-disc ratio, a measure of glaucoma severity.
Researchers were able to validate their results in the Penn Medicine BioBank, an in-house repository of genetic information linked to health records. It features a diverse collection of genetic material.
O’Brien said Penn is sharing its genetic database with other researchers studying diseases that over-affect African-ancestry populations in the hope that the information can influence new clinical approaches. “These collaborations are resulting in much more research on the health of an historically understudied population,” O’Brien said.
O’Brien’s team is now doing research to discover how exactly the three genes they’ve identified contribute to disease risk and severity.
The research was funded by the National Eye Institute and the Vision Research Core Grant.
Related: Glaucoma is Undertreated Among Minorities | AAO 2023
Patients with glaucoma who are Black, Hispanic, and Native American have worse vision outcomes and less disease monitoring, according to separate research presented in November at the annual meeting of the American Academy of Ophthalmology.
Researchers at Johns Hopkins, Wilmer Eye Institute and Harvard University, Massachusetts Eye and Ear Institute evaluated data on nearly 1 million patients. They found that Black and Hispanic patients were about 30% more likely to develop poor vision or receive a low vision diagnosis, and Black patients were 45% more likely to require invasive glaucoma surgery.
Black and Hispanic patients were less likely to receive outpatient eye exams and optical coherence tomography tests, which are used for disease monitoring but were more likely to have inpatient/emergency department encounters compared with White patients.
Don’t Overlook the Importance of Annual Dilated Retinal Exams
July 15th 2024The annual dilated retinal exam, a unique tool which uses drops to dilate the pupil, is not just about eye health. It offers a comprehensive view of a member's overall well-being, potentially identifying serious health issues at an early stage.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
The active ingredient in Ozempic and Wegovy is linked to nonarteritic anterior ischemic optic neuropathy (NAION), the second most common form of optic neuropathy. This is apparently the first study to link semaglutide to the eye condition.
Read More